全身磁共振成像联合血清学随访早期识别冒烟型骨髓瘤进展以避免终末器官损伤
这项前瞻性观察队列研究(NCT01374412)于2014至2020年纳入96例冒烟型骨髓瘤患者,基线及此后每6个月进行全身磁共振成像和血清学随访。22例进展为多发性骨髓瘤,其中7例(32%)仅符合SLiM标准而无终末器官损伤;15例(68%)进展时仍存在终末器官损伤。更新后的疾病定义使进展时发生终末器官损伤的比例降低三分之一。
要点
- 96例冒烟型骨髓瘤患者接受全身磁共振成像和血清学随访,22例进展为多发性骨髓瘤。
- 7例(32%)仅符合SLiM标准而无终末器官损伤,其中4例(57%)因大于1个局灶性病变或增大的局灶性病变进展。
- 更新后的疾病定义使进展时终末器官损伤比例降低三分之一,全身磁共振成像有助于识别无终末器官损伤的进展者。
核心结论
- 更新后的疾病定义使冒烟型骨髓瘤患者进展为多发性骨髓瘤时发生终末器官损伤的比例降低三分之一。
- 全身磁共振成像(wb-MRI)是识别无终末器官损伤即进展为多发性骨髓瘤的冒烟型骨髓瘤患者的重要工具。
研究设计与样本
- 前瞻性观察队列研究(ClinicalTrials.gov标识NCT01374412),2014年至2020年间纳入96例冒烟型骨髓瘤(SMM)患者。
- 患者在基线及此后每6个月接受全身磁共振成像(wb-MRI)和血清学随访。
主要发现
- 随访期间共22例患者进展为多发性骨髓瘤(MM)。
- 22例进展患者中7例(32%)仅符合SLiM标准而无终末器官损伤。
- 仅符合SLiM标准进展的7例中,4例(57%)因大于1个局灶性病变(FL)或增大的FL进展,3例(43%)因血清游离轻链比值≥100进展。
- 22例进展患者中15例(68%)进展时仍存在终末器官损伤。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The definition of multiple myeloma (MM) was updated in 2014, with the intent to enable earlier treatment and thereby avoid appearance of end-organ damage at progression from smouldering multiple myeloma (SMM) to MM. The purpose of this study was to investigate to which extent the development of end-organ damage at progression to MM was reduced under the updated guidelines. In this prospective observational cohort study (ClinicalTrials.gov Identifier: NCT01374412), between 2014 and 2020, 96 SMM patients prospectively underwent whole-body magnetic resonance imaging (wb-MRI) and serological follow-up at baseline and every 6 months thereafter. A total of 22 patients progressed into MM during follow-up, of which seven (32%) showed SLiM-criteria only but no end-organ damage. Four (57%) of the seven patients who progressed by SLiM-criteria only progressed with >1 focal lesion (FL) or a growing FL, and three (43%) due to serum free light-chain-ratio ≥100. Fifteen (68%) out of 22 patients who progressed still suffered from end-organ damage at progression. The updated disease definition reduced the proportion of SMM patients suffering from end-organ damage at progression to MM by one third. wb-MRI is an important tool for detection of SMM patients who progress to MM without end-organ damage.
引用
- Wennmann M, Goldschmidt H, Mosebach J, et al. Whole-body magnetic resonance imaging plus serological follow-up for early identification of progression in smouldering myeloma patients to prevent development of end-organ damage. Br J Haematol. 2022. PMID: 35608264. doi:10.1111/bjh.18232
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。